TRK-IN-32
TRK-IN-32 is a potent TRK inhibitor. TRK-IN-32 potently inhibits TRKWT, TRKG595R and TRKG667C with IC50 values of 0.08 nM, 2.14 nM and 0.68 nM, respectively. TRK-IN-32 also demonstrates antiproliferative activity against a panel of Ba/F3 cell lines transformed with wild type, xDFG, solvent-front as well as gatekeeper mutant TRK fusion proteins. TRK-IN-32 induces apoptosis of Ba/F3-TRKAWT and Ba/F3-TRKAG667C cells.TRK-IN-32 can be used for the study of various cancers (such as thyroid cancer, secretory breast carcinoma).
For research use only. We do not sell to patients.
- CAS No.: 3044124-79-7
- Formula: C19H18FN7
- Molecular Weight:363.39
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
TRK-IN-32 (Compound 15m) exhibits moderate human liver microsomal stability (t1/2 = 33.8 min)[1].
TRK-IN-32 exhibits anti-proliferative efficacy against Ba/F3 cell lines, with an IC50s of 1.24 (Ba/F3-ETV6-TRKAWT), 0.35 (Ba/F3-ETV6-TRKBWT), 24.26 (Ba/F3-LMNA-TRKAG595R), 10.24 (Ba/F3-LMNA-TRKAG667C) and 1.06 (Ba/F3-LMNA-TRKAF589L) nM[1].
TRK-IN-32 (0-10 nM) effectively blocks the TRKAWT and TRKAG667C autophosphorylation in cells at relatively low concentrations as well as phosphorylation of their downstream molecules AKT, PLCγ1 and ERK in Ba/F3 cells expressing TRKAWT and TRKAG667C fusion mutant[1].
TRK-IN-32 (0-500 nM, 48 h) strongly induces Ba/F3-CD74-TRKA and Ba/F3-CD74-TRKAG667C cells apoptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Ba/F3-CD74-TRKA and Ba/F3-CD74-TRKAG667C cells
-
Concentration:10, 50, 100, 500 nM
-
Incubation Time:48 h
-
Result:Observed significant apoptosis rates of 18.74% at 100 nM and 35.65% at 500 nM in Ba/F3-CD74-TRKA cells.
Induced noticeable apoptosis rates of 11.22% and 56.25%, respectively. at concentrations of 10 nM and 50 nM in Ba/F3-CD74-TRKAG667C cells.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUC0-t | AUC0-inf | Vd | CL | MRT0-t | MRT0-inf | F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 10 mg/kg | p.o. | 2.43 h | 2.00 h | 1363.33 ng/mL | 5581.58 ng·h/mL | 5582.96 ng·h/mL | 6454.96 mL/kg | 1810.18 mL/h/kg | 2.77 h | 2.78 h | 55.26 % |
| Rat[1] | 2 mg/kg | i.v. | 1.08 h | 0.08 h | 1606.67 ng/mL | 2020.09 ng·h/mL | 2039.54 ng·h/mL | 1510.95 mL/kg | 1007.89 mL/h/kg | 1.36 h | 1.42 h | / |
Chemical Information
-
CAS No. 3044124-79-7
-
Molecular Weight 363.39
-
Formula C19H18FN7
-
SMILES
C[C@@H](C1=CC=C(C=N1)F)NC2=NN3C(C4=NNC(C5CC5)=C4)=CN=C3C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)